Literature DB >> 28258323

Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?

Fumihito Toshima1, Dai Inoue2, Takahiro Komori2, Kotaro Yoshida2, Norihide Yoneda2, Tetsuya Minami2, Osamu Matsui2, Hiroko Ikeda3, Toshifumi Gabata2.   

Abstract

PURPOSE: To retrospectively elucidate the findings useful in determining the tumor grade of pancreatic neuroendocrine tumors (PNETs) by combined assessment of magnetic resonance (MR) and dynamic computed tomography (CT) images.
MATERIALS AND METHODS: Eighty-nine patients with PNETs (96 lesions) were included, and classified as G1, 59; G2, 29; and G3, 8 lesions. Image analysis included lesion diameter, shape, enhancement pattern on arterial phase (AP) and delayed phase CT images, calcification, cystic portion, main pancreatic duct dilatation, signal-intensity on T1-, T2-weighted MR images, and appearance of apparent diffusion coefficient (ADC).
RESULTS: Significant differences among G1, G2, and G3 groups were noted in tumor maximal diameter (p < 0.0001), shape (p < 0.0001), enhancement pattern on AP image (p < 0.0001), cystic portion (p = 0.012), and ADC finding. In multivariate analysis, ADC finding was the independent factor (p = 0.002). The combination findings of low ADC ratio (ADC value of the lesion/ADC value of the parenchyma <0.94), not homogeneous hyper-attenuation, lobulated shape, and hyper-intensity on T2-weighted image were suggestive of G2 or G3 with a probability of 100%. Conversely, all lesions with high ADC ratio and small size (≤25 mm) belonged to the G1 group.
CONCLUSION: Combined assessment of MR and CT findings could improve the prediction of tumor grading in PNETs.

Entities:  

Keywords:  Computed tomography (CT); Magnetic resonance imaging (MRI); Neuroendocrine carcinoma; Neuroendocrine tumors G1; Neuroendocrine tumors G2; Pancreatic neuroendocrine tumors

Mesh:

Year:  2017        PMID: 28258323     DOI: 10.1007/s11604-017-0627-x

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  26 in total

1.  Intravoxel incoherent motion diffusion-weighted imaging of pancreatic neuroendocrine tumors: prediction of the histologic grade using pure diffusion coefficient and tumor size.

Authors:  Eui Jin Hwang; Jeong Min Lee; Jeong Hee Yoon; Jung Hoon Kim; Joon Koo Han; Byung Ihn Choi; Kyoung-Bun Lee; Jin-Young Jang; Sun-Whe Kim; Marcel Dominik Nickel; Berthold Kiefer
Journal:  Invest Radiol       Date:  2014-06       Impact factor: 6.016

2.  Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification.

Authors:  Yanji Luo; Zhi Dong; Jie Chen; Tao Chan; Yuan Lin; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2014-07-22       Impact factor: 5.315

3.  Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade.

Authors:  Koji Takumi; Yoshihiko Fukukura; Michiyo Higashi; Junnichi Ideue; Tomokazu Umanodan; Hiroto Hakamada; Ichiro Kanetsuki; Takashi Yoshiura
Journal:  Eur J Radiol       Date:  2015-05-14       Impact factor: 3.528

4.  Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics.

Authors:  Yi Wang; Zongming E Chen; Vahid Yaghmai; Paul Nikolaidis; Robert J McCarthy; Laura Merrick; Frank H Miller
Journal:  J Magn Reson Imaging       Date:  2011-05       Impact factor: 4.813

5.  Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour.

Authors:  Dong Wook Kim; Hyoung Jung Kim; Kyung Won Kim; Jae Ho Byun; Ki Byung Song; Ji Hoon Kim; Seung-Mo Hong
Journal:  Eur Radiol       Date:  2014-12-03       Impact factor: 5.315

6.  EUS-guided FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery.

Authors:  José Celso Ardengh; Gustavo Andrade de Paulo; Angelo Paulo Ferrari
Journal:  Gastrointest Endosc       Date:  2004-09       Impact factor: 9.427

7.  Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.

Authors:  Joshua S Hill; James T McPhee; Theodore P McDade; Zheng Zhou; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

8.  Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors.

Authors:  Stefano La Rosa; Catherine Klersy; Silvia Uccella; Linda Dainese; Luca Albarello; Angelica Sonzogni; Claudio Doglioni; Carlo Capella; Enrico Solcia
Journal:  Hum Pathol       Date:  2008-08-20       Impact factor: 3.466

9.  The ENETS guidelines: the new TNM classification system.

Authors:  Guido Rindi
Journal:  Tumori       Date:  2010 Sep-Oct

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  8 in total

1.  Magnetic resonance imaging radiomic analysis can preoperatively predict G1 and G2/3 grades in patients with NF-pNETs.

Authors:  Yun Bian; Jing Li; Kai Cao; Xu Fang; Hui Jiang; Chao Ma; Gang Jin; Jianping Lu; Li Wang
Journal:  Abdom Radiol (NY)       Date:  2020-08-17

2.  Noncontrast Radiomics Approach for Predicting Grades of Nonfunctional Pancreatic Neuroendocrine Tumors.

Authors:  Yun Bian; Zengrui Zhao; Hui Jiang; Xu Fang; Jing Li; Kai Cao; Chao Ma; Shiwei Guo; Li Wang; Gang Jin; Jianping Lu; Jun Xu
Journal:  J Magn Reson Imaging       Date:  2020-04-28       Impact factor: 4.813

Review 3.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

4.  Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors?

Authors:  Riccardo De Robertis; Bogdan Maris; Nicolò Cardobi; Paolo Tinazzi Martini; Stefano Gobbo; Paola Capelli; Silvia Ortolani; Sara Cingarlini; Salvatore Paiella; Luca Landoni; Giovanni Butturini; Paolo Regi; Aldo Scarpa; Giampaolo Tortora; Mirko D'Onofrio
Journal:  Eur Radiol       Date:  2018-01-19       Impact factor: 5.315

Review 5.  New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.

Authors:  Mohammed Saleh; Priya R Bhosale; Motoyo Yano; Malak Itani; Ahmed K Elsayes; Daniel Halperin; Emily K Bergsland; Ajaykumar C Morani
Journal:  Abdom Radiol (NY)       Date:  2020-10-23

6.  Homogenously isoattenuating insulinoma on biphasic contrast-enhanced computed tomography: Little benefits of diffusion-weighted imaging for lesion detection.

Authors:  Zhenshan Shi; Xiumei Li; Ruixiong You; Yueming Li; Xianying Zheng; Kamisha Ramen; Vikash Sahadeo Loosa; Dairong Cao; Qunlin Chen
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

7.  Pancreatic Neuroendocrine Neoplasm Invading the Entire Main Pancreatic Duct Diagnosed by a Preoperative Endoscopic Biopsy.

Authors:  Tomoya Kimura; Mitsuru Sugimoto; Tadayuki Takagi; Rei Suzuki; Naoki Konno; Hiroyuki Asama; Yuki Sato; Hiroki Irie; Jun Nakamura; Mika Takasumi; Minami Hashimoto; Tsunetaka Kato; Yasuhide Kofunato; Takashi Kimura; Shoki Yamada; Yuko Hashimoto; Shigeru Marubashi; Takuto Hikichi; Hiromasa Ohira
Journal:  Intern Med       Date:  2020-05-23       Impact factor: 1.271

8.  Quantitative Computed Tomography Image Analysis to Predict Pancreatic Neuroendocrine Tumor Grade.

Authors:  Alessandra Pulvirenti; Rikiya Yamashita; Jayasree Chakraborty; Natally Horvat; Kenneth Seier; Caitlin A McIntyre; Sharon A Lawrence; Abhishek Midya; Maura A Koszalka; Mithat Gonen; David S Klimstra; Diane L Reidy; Peter J Allen; Richard K G Do; Amber L Simpson
Journal:  JCO Clin Cancer Inform       Date:  2021-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.